The combined oral contraceptive pill containing drospirenone and ethinyl estradiol plus levomefolate calcium

Bibliography

• U.S. Preventive Services Task Force. Folic acid for the prevention of neural tube defects: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009;150:626-31
   PubMed Web of Science ®Google Scholar
• Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29-38
   PubMed Web of Science ®Google Scholar
• Bachmann G, Sulak P, Sampson-Landers C, Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 μg ethinylestradiol and 3 mg drospirenone. Contraception 2004;70:191-8
   PubMed Web of Science ®Google Scholar
• Parsey K, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 2000;61:105-11
   PubMed Web of Science ®Google Scholar
• Diefenback K, Trummer D, Ebert F, Changes in folate levels following a 24-week co-administration of Yasmin and levomefolate calcium 0.451 mg or folic acid 400 mcg. Eur J Contracept Reprod Health Care 2010;15(Suppl):158-9
   Google Scholar
• Diefenbach K, Trummer D, Ebert F, Changes info late levels following cessation of Yasmin and levomefolate calcium 0.451 mg or folic acid 400 mcg co-administration. Eur J Contracept Reprod Health Care 2010;15(Suppl):157-8
   PubMed Web of Science ®Google Scholar
• Marr J, Sampson-Landers C, Diefenbach K. Folate and homocysteine levels after 24 weeks administration of YAZ + levomefolate calcium 0.451 mg. Eur J Contracept Reprod Health Care 2010;15(Suppl):159
   Google Scholar
• Sitruk-Ware R, Nath A. The use of newer progestins for contraception. Contraception 2010;82:410-17
   PubMed Web of Science ®Google Scholar
• Fuhrmann U, Krattenmacher R, Slater EP, The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996;54:243-51
   PubMed Web of Science ®Google Scholar
• Muhn P, Fuhrmann U, Fritzemeier K, Drospirenone: a Novel Progestogen with antimineralocorticoid and antiandrogenic activity. Ann NY Acad Sci 1995;761:311-35
   PubMed Web of Science ®Google Scholar
• Bachmann G, Sulak P, Sampson-Landers C, Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 mug ethinylestradiol and 3 mg drospirenone. Contraception 2004;70:191-8
   PubMed Web of Science ®Google Scholar
• Berlex, Inc.: (drospirenone/ethinyl estradiol/levomefolate calcium) prescribing information. Berlex, Inc., Montvile (NJ) USA (2010). Available from: http://berlex.bayerhealthcare.com/html/products/pi/fhc/Beyaz _PI.pdf
   Google Scholar
• Appendix B Criteria sets and axes provided for further study Premenstrual Dysphoric Disorder Diagnostic and statistical manual of mental disorders DSM-IV-TR. 4th edition. American Psychiatric Association; Washington, DC: 2000
   Google Scholar
• Joffe H, Cohen L, Harlow B. Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. Am J Obstet Gynecol 2003;189:1523-30
   PubMed Web of Science ®Google Scholar
• Yonkers K, Brown C, Pearlstein T, Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005;106:492-501
   PubMed Web of Science ®Google Scholar
• Pearlstein T, Bachmann G, Zacur H, Yonkers K. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005;72:414-21
   PubMed Web of Science ®Google Scholar
• Maloney JM, Dietze P, Watson D. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen. Obstet Gynecol 2008;112:773-80
   PubMed Web of Science ®Google Scholar
• Lucky A, Koltun W, Thiboutot D, A combined oral contraceptive containing 3-mg drospirenone/20-mug ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment. Cutis 2008;82:143-50
   PubMed Web of Science ®Google Scholar
• CDC Vital Statistics. Use of contraception in the United States: 1982 – 2008. U.S. Department of Health and Human Services Center for Disease Control and Prevention National Center for Health Statistics. 2010 Series 23, no 29
   Google Scholar
• Mills J, Von Kohorn I, Conley M, Low vitamin B-12 concentrations in patients without anemia: the effect of folic acid fortification of grain. Am J Clin Nutr 2003;77:1474-7
   PubMed Web of Science ®Google Scholar
• Vollset SE, Gjessing HK, Tandbert A, Folate supplementation and twin pregnancies. Epidemiology 2005;16:201-5
   PubMed Web of Science ®Google Scholar
• Dinger J, Heinemann L, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance study on oral contraceptives base on 142,475 women-years of observation. Contraception 2007;75:344-54
   PubMed Web of Science ®Google Scholar
• Heinemann L, Dinger J. Range of published estimates of venous thromboembolism incidence in young women. Contraception 2007;75:328-36
   PubMed Web of Science ®Google Scholar
• Seeger J, Loughlin J, Eng M, Risk of Thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol 2007;110:587-93
   PubMed Web of Science ®Google Scholar
• Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: National follow-up study. BMJ 2009;339:b2890
   PubMed Web of Science ®Google Scholar
• Jick S, Hernandez R. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011;340:d2151
   Web of Science ®Google Scholar
• Parkin L, Sharples K, Hernandez R, Jick S. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011;340:d2139
   Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme W, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. NEJM 1999;341:709-17
   PubMed Web of Science ®Google Scholar
• Juulink D, Mamdani M, Lee D, Rates of Hyperkalemia after publication of the randomized aldactone evaluation study. NEJM 2004;351:543-51
   PubMed Web of Science ®Google Scholar
• Loughlin J, Seeger J, Eng M, Risk of hyperkalemia in women taking ethinylestradiol/drospirenon and other oral contraceptives. Contraception 2008;78:377-83
   PubMed Web of Science ®Google Scholar
• Schurmann R, Blode H, Benda N, Effect of drospirenone on serum potassium and drospirenone pharmacokinetics in women with normal or impaired renal function. J Clin Pharmacol 2006;46:867-75
   PubMed Web of Science ®Google Scholar
• Hatcher R. Contraceptive technology. Ardent Media, Inc; New York: 2007
   Google Scholar
• Burris H, Werler M. U.S. provider reported folic acid or multivitamin ordering for non-pregnant women of childbearing age: NAMCS and NHAMCS, 2005-2006. Matern Child Health J 2011;15:352-9
   PubMed Web of Science ®Google Scholar
• ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 44, July 2003. Obstet Gynecol 2003;102:203-13
   PubMedGoogle Scholar